Tirzepatide [Peptide]

Description

What is Tirzepatide?

Tirzepatide (LY3298176), marketed pharmaceutically as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management) by Eli Lilly and Company, is a synthetic 39-amino-acid peptide classified as a dual glucose-dependent insulinotropic polypeptide / glucagon-like peptide-1 (GIP/GLP-1) receptor agonist, also referred to as a “twincretin.” Its amino acid sequence is based on the endogenous GIP backbone: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20 diacid linker)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2. Non-coded 2-aminoisobutyric acid (Aib) residues at positions 2 and 13 replace alanine to prevent dipeptidyl peptidase-4 (DPP-4) degradation and extend metabolic stability. A C20 fatty diacid moiety conjugated via a (AEEA)₂-γGlu linker at the epsilon-amino group of Lys20 enables once-weekly dosing through albumin binding, yielding a pharmacological half-life of approximately 5 days.

Tirzepatide received FDA approval on May 13, 2022, as Mounjaro for the treatment of adults with type 2 diabetes, and subsequently as Zepbound in November 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. These approvals are for the pharmaceutical formulations at defined doses. Research-grade Tirzepatide supplied by RCDbio is not a pharmaceutical product and is not approved or intended for human therapeutic use. It is not a dietary supplement and is not intended for self-administration. All RCDbio research compounds are supplied strictly for laboratory and research purposes only.

Chemical Properties

Property	Detail
Product Type	Synthetic Dual Receptor Agonist Peptide (GIP/GLP-1, Twincretin)
Product Name	Tirzepatide
Application	Scientific / Research Use Only
CAS Number	2023788-19-2
Molar Mass	4813.527 g/mol (free base)
Chemical Formula	C225H348N48O68
PubChem CID	156588324
Amino Acid Count	39 amino acids (GIP-backbone derived; C-terminal amide)
Non-Coded Residues	Aib at positions 2 and 13 (DPP-4 resistance)
Lipid Conjugate	C20 fatty diacid via (AEEA)₂-γGlu linker at Lys20 epsilon-amino group
Receptor Targets	GIPR (greater affinity); GLP-1R (comparable to endogenous GIP at GLP-1R; biased toward cAMP vs β-arrestin)
Synonyms	LY3298176; Mounjaro (pharmaceutical); Zepbound (pharmaceutical); Twincretin
Elimination Half-Life	~5 days (albumin binding via C20 fatty diacid; enables once-weekly dosing)
Physical Form	Lyophilized white to off-white powder
Solubility	Soluble in sterile water and PBS; compatible with standard peptide reconstitution buffers
Storage (Lyophilized)	−20°C; sealed container; protected from light and moisture
Storage (Reconstituted)	4°C; use within 48–72 hours; avoid repeated freeze-thaw cycles
Purity	≥98% (HPLC verified, independent third-party laboratory analysis; COA available per batch)
WADA Status	Prohibited under S2 (GLP-1 receptor agonists / Peptide Hormones and Related Substances) and S0 (Non-Approved Substances for research-grade non-pharmaceutical formulations) of the 2026 WADA Prohibited List. Pharmaceutical Mounjaro/Zepbound may qualify for a TUE; research-grade material is not eligible. Verify at GlobalDRO.com.

How Does Tirzepatide Work?

Tirzepatide’s mechanism is defined by simultaneous engagement of two incretin receptor systems – GIPR and GLP-1R – with distinct signalling profiles at each receptor that together produce metabolic effects exceeding those of GLP-1R monotherapy.

GIP Receptor (GIPR) Pathway

Tirzepatide demonstrates greater binding affinity at GIPR compared to GLP-1R, mimicking the signalling of endogenous GIP at the GIP receptor with high fidelity. GIPR activation stimulates glucose-dependent insulin secretion from pancreatic beta cells via Gαs/cAMP/PKA cascades, and is also investigated for complementary effects on adipose tissue lipid metabolism, energy partitioning, and gastrointestinal motility in preclinical and clinical research models [Frías et al., 2021]. The GIP receptor component is considered central to Tirzepatide’s superior glycaemic and weight outcomes compared to GLP-1R monoagonists in head-to-head clinical trial comparisons.

GLP-1 Receptor (GLP-1R) Pathway and Biased Signalling

At the GLP-1R, Tirzepatide demonstrates pharmacological bias toward cAMP generation rather than β-arrestin recruitment – a signalling characteristic distinct from endogenous GLP-1 and from semaglutide. This biased agonism at GLP-1R is proposed as a mechanistic contributor to Tirzepatide’s differentiated metabolic profile. GLP-1R activation mediates glucose-dependent insulin secretion, glucagon suppression in a glucose-dependent manner, delayed gastric emptying, and modulation of hypothalamic appetite-regulatory circuits in preclinical models and clinical populations [Jastreboff et al., 2022].

Complementary Dual Receptor Synergy

In signalling studies and preclinical models, the combined GIPR and GLP-1R agonism of Tirzepatide has been characterised as producing greater reductions in hyperglycaemia, body weight, and adipose tissue mass than selective GLP-1R agonism alone. The synergistic or additive effects are attributed to complementary insulin secretion pathways, distinct downstream signalling cascades at each receptor, and the combined modulation of food intake, gastric emptying, and energy expenditure through two parallel incretin systems.

Albumin Binding and Extended Half-Life

The C20 fatty diacid moiety at Lys20 non-covalently binds circulating albumin, reducing renal filtration and extending Tirzepatide’s half-life to approximately 5 days – enabling once-weekly subcutaneous dosing in both clinical trial and approved pharmaceutical protocols.

Key Research Findings

In preclinical, in vitro, and clinical research contexts, Tirzepatide has been associated with the following observations:

• Dual receptor engagement: GIPR and GLP-1R agonism characterised in cell-based signalling assays; biased cAMP signalling at GLP-1R (vs β-arrestin) distinguished from semaglutide and endogenous GLP-1 in molecular pharmacology studies [Frías et al., 2021].
• Type 2 diabetes glycaemic control: SURPASS Phase 3 trials demonstrated HbA1c reductions of 1.9–2.6% and body weight reductions of 6.6–13.9 kg at 5–15 mg doses, with superiority over semaglutide 1 mg at matched time points [Frías et al., 2021].
• Obesity weight reduction: In the SURMOUNT-1 Phase 3 trial (72 weeks), participants receiving 15 mg Tirzepatide weekly achieved a mean body weight reduction of 20.9% – the largest weight loss recorded in any randomised obesity drug trial at the time of publication [Jastreboff et al., 2022].
• Cardiovascular outcomes: SURPASS-CVOT data demonstrated non-inferiority for major adverse cardiovascular events (MACE) vs insulin degludec in high-risk T2D patients; cardiovascular benefit studies (SURMOUNT-MMO) are ongoing.
• Hepatic fat and NASH/MASH: Phase 2 SYNERGY-NASH data demonstrated significant reductions in liver fat content and NASH resolution in participants with biopsy-confirmed NASH.

All findings listed above are derived from preclinical, in vitro, and controlled clinical trial data. Research-grade Tirzepatide is not a pharmaceutical product and is not approved or intended for human therapeutic use outside of approved clinical protocols. These observations do not constitute claims of efficacy or safety for research-grade material.

What are the Potential Research Applications of Tirzepatide?

In controlled laboratory and clinical research environments, Tirzepatide has been investigated for the following research applications. These are observed in preclinical and clinical trial contexts and do not constitute claims of efficacy or safety for research-grade material outside approved clinical protocols.

Dual Receptor Agonism and Biased Signalling Studies: Tirzepatide serves as the primary reference compound for studies characterising simultaneous GIPR and GLP-1R engagement and biased agonism at GLP-1R. It is employed in receptor binding assays, cAMP reporter systems, β-arrestin recruitment assays, and structural pharmacology investigations to characterise twincretin signalling mechanisms.

Incretin Biology and Insulin Secretion Research. In isolated pancreatic beta cell preparations and rodent in vivo models, Tirzepatide is investigated for glucose-dependent insulin secretion dynamics, GIP/GLP-1 receptor co-activation synergy, and the relative contributions of each receptor to insulin secretory responses under varying glucose conditions.

Obesity and Adipose Tissue Metabolism Research. In preclinical rodent models and Phase 3 clinical research, Tirzepatide is investigated for its effects on adipose tissue lipolysis, energy homeostasis, hypothalamic appetite circuit modulation, and visceral fat reduction. Research examines how dual versus single incretin agonism alters the profile of adipose tissue response.

Non-Alcoholic / Metabolic Dysfunction-Associated Steatohepatitis (NASH/MASH): In preclinical fatty liver models and Phase 2–3 clinical trials, Tirzepatide is investigated for hepatic fat reduction, liver enzyme normalisation, NASH resolution on biopsy, and fibrosis stage improvement. Research examines the hepatoprotective mechanisms of combined GIPR/GLP-1R engagement.

Comparative Incretin Pharmacology and SAR Studies. As a dual agonist reference compound, Tirzepatide is employed in comparative studies against GLP-1R monoagonists (semaglutide, liraglutide) and the triple agonist Retatrutide, to characterise how each incretin receptor combination alters metabolic outcomes, receptor signalling profiles, and body composition in experimental systems.

What are the Potential Side Effects of Tirzepatide?

The following observations are derived from Phase 3 clinical trial data (SURPASS and SURMOUNT programmes) for the pharmaceutical formulation. Research-grade material side effects have not been independently characterised.

• Gastrointestinal adverse events – nausea, vomiting, diarrhoea, constipation, and abdominal discomfort – were the most frequently reported adverse events across SURPASS and SURMOUNT trials; dose-dependent in frequency and predominantly mild-to-moderate; consistent with dual incretin receptor pharmacology
• Hypoglycaemia risk is low in non-insulin-treated populations but increases when combined with insulin or insulin secretagogues; the glucose-dependent mechanism reduces but does not eliminate hypoglycaemia risk
• Injection site reactions were reported at low frequency in clinical trials; consistent with other subcutaneous peptide formulations
• Transient heart rate increases observed, consistent with GLP-1R agonist class effects; magnitude and clinical significance under investigation
• Pancreatitis risk cannot be excluded; GLP-1R agonist class members have been associated with pancreatitis reports; participants with active pancreatitis were excluded from trials
• Thyroid C-cell tumours observed in rodent carcinogenicity studies at doses producing sustained exposure; human clinical relevance not established; patients with personal or family history of medullary thyroid carcinoma were excluded from trials

No human safety data has been established for research-grade Tirzepatide outside approved clinical trial protocols. The adverse event observations above are from pharmaceutical formulation trials and should not be directly extrapolated to research-grade material.

Risk & Handling

Handling Precautions

Research-grade Tirzepatide should only be handled by trained laboratory personnel. Appropriate personal protective equipment is required: nitrile gloves, a laboratory coat, and eye protection at a minimum. When working with lyophilized powder, use within a laminar flow cabinet or clean area to minimise inhalation risk. Avoid aerosol generation during reconstitution. The fatty acid conjugate moiety contributes amphiphilic character; avoid contact with surfaces that adsorb lipophilic molecules.

Exposure Risks

Risk Tier: MODERATE

Tirzepatide is a pharmacologically active dual incretin receptor agonist with well-characterised effects at GIPR and GLP-1R. Accidental exposure at research concentrations may engage these receptors in tissues expressing them, producing gastrointestinal effects, altered insulin secretion, and gastric motility changes consistent with incretin pharmacology. No human safety data has been established for research-grade Tirzepatide outside of approved clinical protocols.

Storage

• Lyophilized form: Store at −20°C in original sealed, light-protected container with desiccant
• Reconstituted form: Store at 4°C; use within 48–72 hours of reconstitution
• Do not subject to repeated freeze-thaw cycles; peptide backbone and fatty acid conjugate integrity may both be affected
• Protect from prolonged light exposure and oxidative conditions
• Store away from strong acids, bases, and oxidising agents

Frequently Asked Questions

Q: What is Tirzepatide, and what is it being investigated for in research? A: Tirzepatide (LY3298176) is a synthetic 39-amino-acid dual GIP/GLP-1 receptor agonist peptide, FDA-approved pharmaceutically as Mounjaro (T2D, 2022) and Zepbound (obesity, 2023). Research-grade Tirzepatide is investigated in preclinical and in vitro contexts for dual incretin receptor pharmacology, biased GLP-1R signalling, insulin secretion dynamics, and metabolic pathway studies. Research-grade material is not a pharmaceutical product and is not approved for human use.

Q: How does Tirzepatide differ from Semaglutide? A: Semaglutide is a GLP-1R monoagonist. Tirzepatide adds GIPR agonism as a second mechanism (twincretin). In head-to-head clinical trials, Tirzepatide demonstrated superior HbA1c reduction and weight loss compared to semaglutide 1 mg at matched time points. At the GLP-1R, Tirzepatide also shows biased signalling toward cAMP rather than β-arrestin recruitment – a mechanistic difference not seen with semaglutide.

Q: Is Tirzepatide approved by the FDA? A: Yes – the pharmaceutical formulations. Mounjaro (tirzepatide) received FDA approval in May 2022 for type 2 diabetes. Zepbound received FDA approval in November 2023 for chronic weight management. Research-grade Tirzepatide from RCDbio is not a pharmaceutical product and is not approved for human use.

Q: What is the half-life of Tirzepatide? A: Tirzepatide has an elimination half-life of approximately 5 days in clinical pharmacokinetic studies, achieved through the C20 fatty diacid moiety at Lys20 that promotes albumin binding and reduces renal filtration. This enables once-weekly subcutaneous dosing in clinical trials and approved pharmaceutical protocols.

Q: What were the key SURMOUNT-1 findings? A: In the SURMOUNT-1 Phase 3 trial (Jastreboff et al., 2022, NEJM, PMID 35658024), participants without diabetes receiving 15 mg Tirzepatide weekly for 72 weeks achieved a mean body weight reduction of 20.9% – at the time of publication, the largest weight loss recorded in any randomised obesity drug trial. All three doses (5, 10, 15 mg) demonstrated significant and sustained weight reduction versus placebo.

Q: How should research-grade Tirzepatide be stored? A: Lyophilized Tirzepatide should be stored at −20°C in a sealed, light-protected container with desiccant. Once reconstituted, store at 4°C and use within 48–72 hours. Avoid repeated freeze-thaw cycles as both the peptide backbone and fatty acid conjugate may degrade. Protect from oxidative conditions.

Q: What is Tirzepatide’s WADA status? A: Tirzepatide is prohibited under S2 (GLP-1 receptor agonists and related incretin peptides) and under S0 (Non-Approved Substances for research-grade, non-pharmaceutical formulations) of the 2026 WADA Prohibited List. The approved pharmaceutical formulations (Mounjaro/Zepbound) may qualify for a Therapeutic Use Exemption (TUE) under specific medical conditions; research-grade material is not eligible. Verify at GlobalDRO.com.

Related Research Compounds

Researchers investigating Tirzepatide may also be interested in the following compounds currently available for laboratory research at RCDbio:

• Retatrutide – A triple GLP-1R/GIPR/GCGR agonist peptide (LY3437943) investigated for comparative triple vs. dual agonism pharmacology; the next-generation mechanistic comparator for Tirzepatide research.
• Semaglutide – A GLP-1R monoagonist peptide investigated in preclinical metabolic models; the primary head-to-head clinical comparator for Tirzepatide in the SURPASS programme.

All products listed are for laboratory and research purposes only.

References

1. Frías, J. P., Davies, M. J., Rosenstock, J., Manghi, F. C. P., Landó, L. F., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://pubmed.ncbi.nlm.nih.gov/34170647/

2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://pubmed.ncbi.nlm.nih.gov/35658024/

3. Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., Kuchibhotla, U., Moyers, J. S., Benson, C. T., Gimeno, R. E., & Haupt, A. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14. https://pubmed.ncbi.nlm.nih.gov/30473097/

4. Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Landó, L. F. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5): A Randomised Clinical Trial. JAMA, 327(6), 534–545. https://pubmed.ncbi.nlm.nih.gov/35133415/ 

Disclaimer

Tirzepatide is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition. Research-grade Tirzepatide is not a pharmaceutical product and is not equivalent to Mounjaro or Zepbound.

The Food and Drug Administration has approved tirzepatide as Mounjaro and Zepbound pharmaceutical formulations. Research-grade material from RCDbio is not an approved product and is not intended for human use in any form. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co